You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昂利康(002940.SZ):擬與科瑞生物共同受讓“新型藥物遞送系統及製備方法”的技術成果並組建合資公司
格隆匯 05-11 19:03

格隆匯5月11日丨昂利康(002940.SZ)公佈,基於公司發展戰略和未來研發佈局,為增強公司的可持續發展能力和核心競爭力,公司擬與關聯方科瑞生物作為共同受讓方和讓與方中南大學簽訂《技術轉讓(技術祕密)合同》,與科瑞生物共同受讓“新型藥物遞送系統及製備方法”的技術成果(“標的技術成果”),並組建合資公司,積極探索在醫藥創新技術平台領域的早期研究。

《技術轉讓合同》中約定技術轉讓費總額為3億元人民幣,支付形式按首期款+里程碑付款+後期商業獲益提成形式支付,合資公司將作為受讓標的技術成果的具體項目實施主體。公司與科瑞生物擬以自有或自籌資金按50%:50%出資比例共同設立合資公司,該合資公司註冊資本為2000萬元人民幣,後續,雙方將根據項目實際研發進度等情況調整註冊資本。

核酸藥物具有治療效率高、藥物毒性小、特異性強和應用領域廣等突出優點,有望成為繼小分子化學藥和抗體類藥物後第三大類型藥物,而藥物遞送系統則是核酸藥物成藥的關鍵技術之一。

公司此次擬與中南大學、科瑞生物簽訂《技術轉讓合同》,並與科瑞生物共同受讓中南大學原創擁有的“新型藥物遞送系統及製備方法”的技術成果,是公司經過審慎研究後的決策,植物源膽固醇是藥物遞送系統的重要組成成分之一,通過受讓上述技術成果形成具有自主知識產權的核心技術,並結合科瑞生物已在植物源膽固醇領域形成的技術優勢,有助於公司加快新型藥物遞送系統的產業化開發和應用,有助於公司在生物醫藥領域的拓展,能有效增強公司的可持續發展能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account